Medullary Breast Carcinoma
Associated Genetic Biomarkers
NCI Definition: An infiltrating breast carcinoma with a relatively favorable prognosis. It is an uncommon carcinoma, accounting for less than 1% of all infiltrating breast carcinomas. It is well circumscribed, with soft cut surface and often of considerable size. Microscopically, the predominant growth pattern is syncytial with broad anastomosing bands or sheets of malignant cells. The malignant cells are round with abundant cytoplasm and vesicular nuclei. The sheets of malignant cells are associated with a marked lymphoplasmacytic infiltrate. Glandular or tubular structures are absent. 
There is 1 clinical trial for medullary breast carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains medullary breast carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
ER, ERBB2, and HER2 are the most frequent gene inclusion criteria for medullary breast carcinoma clinical trials .
Cyclophosphamide, durvalumab, and epirubicin are the most common interventions in medullary breast carcinoma clinical trials.
Significant Genes in Medullary Breast Carcinoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for medullary breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and medullary breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.